Unknown

Dataset Information

0

Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.


ABSTRACT:

Background

Aberrant DNA repair pathways contribute to malignant transformation or disease progression and the acquisition of drug resistance in multiple myeloma (MM); therefore, these pathways could be therapeutically exploited. Ribonucleotide reductase (RNR) is the rate-limiting enzyme for the biosynthesis of deoxyribonucleotides (dNTPs), which are essential for DNA replication and DNA damage repair. In this study, we explored the efficacy of the novel RNR inhibitor, 4-hydroxysalicylanilide (HDS), in myeloma cells and xenograft model. In addition, we assessed the clinical activity and safety of HDS in patients with MM.

Methods

We applied bioinformatic, genetic, and pharmacological approaches to demonstrate that HDS was an RNR inhibitor that directly bound to RNR subunit M2 (RRM2). The activity of HDS alone or in synergy with standard treatments was evaluated in vitro and in vivo. We also initiated a phase I clinical trial of single-agent HDS in MM patients (ClinicalTrials.gov: NCT03670173) to assess safety and efficacy.

Results

HDS inhibited the activity of RNR by directly targeting RRM2. HDS decreased the RNR-mediated dNTP synthesis and concomitantly inhibited DNA damage repair, resulting in the accumulation of endogenous unrepaired DNA double-strand breaks (DSBs), thus inhibiting MM cell proliferation and inducing apoptosis. Moreover, HDS overcame the protective effects of IL-6, IGF-1 and bone marrow stromal cells (BMSCs) on MM cells. HDS prolonged survival in a MM xenograft model and induced synergistic anti-myeloma activity in combination with melphalan and bortezomib. HDS also showed a favorable safety profile and demonstrated clinical activity against MM.

Conclusions

Our study provides a rationale for the clinical evaluation of HDS as an anti-myeloma agent, either alone or in combination with standard treatments for MM.

Trial registration

ClinicalTrials.gov, NCT03670173, Registered 12 September 2018.

SUBMITTER: Xie Y 

PROVIDER: S-EPMC9097096 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.

Xie Yongsheng Y   Wang Yingcong Y   Xu Zhijian Z   Lu Yumeng Y   Song Dongliang D   Gao Lu L   Yu Dandan D   Li Bo B   Chen Gege G   Zhang Hui H   Feng Qilin Q   Zhang Yong Y   Hu Ke K   Huang Cheng C   Peng Yu Y   Wu Xiaosong X   Mao Zhiyong Z   Shao Jimin J   Zhu Weiliang W   Shi Jumei J  

Journal of biomedical science 20220512 1


<h4>Background</h4>Aberrant DNA repair pathways contribute to malignant transformation or disease progression and the acquisition of drug resistance in multiple myeloma (MM); therefore, these pathways could be therapeutically exploited. Ribonucleotide reductase (RNR) is the rate-limiting enzyme for the biosynthesis of deoxyribonucleotides (dNTPs), which are essential for DNA replication and DNA damage repair. In this study, we explored the efficacy of the novel RNR inhibitor, 4-hydroxysalicylani  ...[more]

Similar Datasets

| S-EPMC1389704 | biostudies-literature
| S-EPMC9247363 | biostudies-literature
| S-EPMC5581671 | biostudies-literature
| S-EPMC6326808 | biostudies-literature
| S-EPMC10191446 | biostudies-literature
| S-EPMC6157621 | biostudies-literature
| S-EPMC3088718 | biostudies-literature
| S-EPMC4209159 | biostudies-literature
2018-01-01 | GSE91389 | GEO
| S-EPMC4234372 | biostudies-literature